Cambridge, Mass., Rotterdam, the Netherlands AND Shanghai, February 13 2025 / Prnewswire/ – Harbor Biomed (“Company”; Hkex: 02142), a global biofarmic company committed to detecting, developing and commercializing new antibody therapeutics that focus on immunology and oncology, announced today the latest progress and update of business.
Based on a preliminary summary of the company’s consolidated management accounts for the finished year December 31 2024Total profit is expected to go between RMB7.3 million AND RMB22 million. During this period, the company reached a high record profit profit[1] BY RMB220 millionreflecting strong financial health and operational efficiency.
The sustainable benefit of the company was mainly addressed by:
- The accelerated growth of its unique business model with continuous strategic partnerships with global pharmaceutical and biotechnical leadership companies.
- A repetitive component of its income in 2024, including revenue from platform -based research and historical payments as cooperation programs prosper.
- Effective cost control and efficient operational management.
In 2025, the company repurchased 8,146,000 shares in the open market, reaching almost ready $ 30 million HK. This reflects confidence in the business perspective of the company and underlines the management’s view that the current evaluation does not fully reflect its internal value.
Target Jingsong wangThe founder, chairman and general manager of Harbor Biomed commented: “Harbor biomed is accelerating it into a sustainable profitable biotechnical engine, driven by our port ratsABOUT Differentiated business platform and model. With more than 19 molecules that progress in the tissue phase globally through partnerships with multinational pharmaceutical and biotechnical companies, the value of our platform continues to be proven. Our strong financial performance underlines the resistance and escalation of our business. Looking forward, we remain committed to advancing future generation antibody technologies to address critical medical needs and to give long -term value to stakeholders. “
|
[1] Money Gain: Net cash entry |
Around the biomed port
Harbor biomed (Hkex: 02142) is a global biofarmic company committed to detecting, developing and commercializing new antibodies that focus on immunology and oncology. The company is building its powerful portfolio and differentiated pipeline through R&D internal skills, collaborations with co-disclosure and co-development partners, and select purchases.
Owner’s antibody technology platformsABOUT Generates fully human monoclonal antibodies in two format forms and two light chains (H2L2), as well as only with heavy chains (HCAB). Relying on HCAB antibodies, HCAB -based immune cells (HBICEABOUT) Bispecific technology of antibodies is capable of providing effects on killing inaccessible tumor from traditional combination therapies. Integration of port miceABOUTand hbiceABOUT With a single B cell cloning platform, our antibody detection engine is very unique and effective for developing therapeutic antibodies of the next generation. For more information, please refer to www.harbourbiomed.com.
declaration
The information included in this press release is only a preliminary assessment from the Board based on the managed consolidated accounts of the company and its subsidiaries for the finished year December 312024 currently available to the company, and is not based on any figures or information that has been revised or confirmed by the Board Audit Committee, either reviewed or audited by company auditors. Current results for the finished year December 312024 may differ from those unveiled in this press release. As such, the above figures are strictly only for information and not for any other purpose.
Biomedi source